儿童特发性膜性肾病诊疗进展
王楠楠 - 临床儿科杂志, 2021 - jcp.xinhuamed.com.cn
儿童特发性膜性肾病诊疗进展 Page 1 · 476 · 临床儿科杂志第39 卷第6 期2021 年6 月J Clin
Pediatr Vol.39 No.6 Jun. 2021 doi:10.3969/j.issn.1000-3606.2021.06.018 膜性肾病(membranous …
Pediatr Vol.39 No.6 Jun. 2021 doi:10.3969/j.issn.1000-3606.2021.06.018 膜性肾病(membranous …
小剂量利妥昔单抗改善早期中高风险膜性肾病疾病进展: 一项探索性研究
徐秋郁， 艾三喜， 王淦淦， 贾淳钰… - 中国临床药理学 …, 2024 - manu41.magtech.com.cn
膜性肾病(membranous nephropathy, MN) 是成人原发性肾病综合征(nephrotic syndrome, NS)
最常见的病因, 近年来研究发现PLA2R 是MN 的关键致病靶抗原, 且其发现给利妥昔单抗 …
最常见的病因, 近年来研究发现PLA2R 是MN 的关键致病靶抗原, 且其发现给利妥昔单抗 …
Obinutuzumab in untreated primary membranous nephropathy: An observational case series
J Hao, J Wang, P Zhou, R Xu, X Chen - Nephrology, 2024 - Wiley Online Library
Background As an initial treatment for primary membranous nephropathy (PMN), there
remains a significant proportion of patients for whom rituximab is not fully effective. Here, we …
remains a significant proportion of patients for whom rituximab is not fully effective. Here, we …
Serum antibody and glomerular antigen of antiphospholipase A2 receptor in Chinese patients with idiopathic membranous nephropathy
Q Zhang, M Wu, Z Hu, X Liu, B Huang… - BioMed Research …, 2020 - Wiley Online Library
Background. M‐type phospholipase A2 receptor (PLA2R) is the first autoantigen responsible
for idiopathic membranous nephropathy (IMN). However, serum PLA2R antibody (PLA2R …
for idiopathic membranous nephropathy (IMN). However, serum PLA2R antibody (PLA2R …
[HTML][HTML] Update on the etiology, classification, and management of glomerular diseases
M Tinawi - Avicenna Journal of Medicine, 2020 - thieme-connect.com
In this brief review, the reader will find a timely update regarding some of the most commonly
encountered glomerular diseases. The review will include an update on the etiology with a …
encountered glomerular diseases. The review will include an update on the etiology with a …
基于“阳化气, 阴成形” 探讨温阳化积法治疗原发性膜性肾病
黄淑贤， 刘宝利 - 现代中医临床, 2024 - xblc.bucm.edu.cn
膜性肾病病因未明者为原发性膜性肾病(PMN), 可归属于“水肿病” 范畴.“阳化气, 阴成形”
理论源于《 素问· 阴阳应象大论篇》, 是对阴阳特性的高度概括.“阳化气” 与“阴成形” …
理论源于《 素问· 阴阳应象大论篇》, 是对阴阳特性的高度概括.“阳化气” 与“阴成形” …
The efficacy of rituximab in the treatment of membranous nephropathy
R Maharjan, JW Wang, IK Shrestha - 2020 - elibrary.nhrc.gov.np
Rituximab is a chimeric monoclonal antibody directed against the CD20 expressed on B
cells, originally used to treat lymphoma but is increasingly used for the treatment of …
cells, originally used to treat lymphoma but is increasingly used for the treatment of …
Combination of rituximab and short-term glucocorticoids in the treatment of anti-phospholipase A2 receptor antibody positive idiopathic membranous nephropathy
Q Ma, M Li, G Xu - Clinical and Experimental Medicine, 2023 - Springer
Rituximab (RTX) has been the first option in idiopathic membranous nephropathy (IMN).
However, the clinical effect was not very satisfactory. This study aimed to explore the clinical …
However, the clinical effect was not very satisfactory. This study aimed to explore the clinical …
[HTML][HTML] Comprehensive antibody profiles as personalized indicators of health and disease
PD Burbelo, J Keller, MJ Iadarola - Discovery Medicine, 2017 - discoverymedicine.com
Comprehensive, robust, and inexpensive clinical tools are needed to monitor human health
and disease. In this review, we propose how a standardized, high-performance antibody …
and disease. In this review, we propose how a standardized, high-performance antibody …
[HTML][HTML] 膜性肾病生物标志物的研究进展
唐钰书， 谢席胜 - Advances in Clinical Medicine, 2023 - hanspub.org
特发性膜性肾病(idiopathic membranous nephropathy, IMN) 是一种常见的免疫性肾脏疾病,
是成人终末期肾病的重要病因之一. 及时诊断, 规范治疗和定期随访关乎患者预后. 关于M …
是成人终末期肾病的重要病因之一. 及时诊断, 规范治疗和定期随访关乎患者预后. 关于M …